Madrigal is a public, clinical-stage biopharmaceutical company pursuing novel therapeutics for the treatment of liver disease.  Madrigal’s lead program, resmetirom, is in ongoing Phase 3 studies and has the potential to be first-to-market for the treatment of non-alcoholic steatohepatitis (NASH).

 

Madrigal’s most advanced clinical candidate, resmetirom, is an oral, liver-directed, thyroid hormone receptor beta (THR-β) selective agonist designed specifically to treat the underlying causes of NASH, while lowering multiple atherogenic lipids. 
 

Phase 2 and emerging Phase 3 clinical data support the potential of resmetirom to become the first-to-market safe, well-tolerated, and efficacious therapy for NASH patients with significant liver fibrosis.

 

Resmetirom’s mechanism of action targets the underlying cause of the disease in the liver by reducing or eliminating liver fat (steatosis) as well as reducing inflammation (hepatic stellate cell infiltration), liver cell ballooning (hepatocyte cell death), and fibrosis.